EOLS Evolus Inc.

Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.

$13.61  -0.19 (-1.38%)
As of 06/22/2021 15:59:56 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  USA
Country of incorporation:  USA
IPO date:  02/08/2018
Outstanding shares:  54,120,312
Average volume:  545,230
Market cap:   $691,116,384
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    30052C107
ISIN:        US30052C1071
Sedol:      BDRJH21

---

Valuation   (See tab for details)

---

PE ratio:   -5.46
PB ratio:   25.94
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%